![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Hergesell O Ritz E
Publisher: Informa Healthcare
ISSN: 1354-3784
Source: Expert Opinion on Investigational Drugs, Vol.10, Iss.12, 2001-12, pp. : 2185-2190
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sevelamer could be worth it in hyperphosphataemia
Inpharma, Vol. 1, Iss. 1636, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
ESRD with hyperphosphataemia: an economic burden
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 505, 2006-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Sevelamer could be worth it in hyperphosphataemia
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 552, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)